| First Author | Puranam KL | Year | 1999 |
| Journal | Mol Genet Metab | Volume | 66 |
| Issue | 4 | Pages | 294-308 |
| PubMed ID | 10191118 | Mgi Jnum | J:282684 |
| Mgi Id | MGI:6383588 | Doi | 10.1006/mgme.1999.2834 |
| Citation | Puranam KL, et al. (1999) CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol Genet Metab 66(4):294-308 |
| abstractText | Juvenile neuronal ceroid lipofuscinosis or Batten disease (JNCL) is a neurodegenerative disorder characterized by blindness, seizures, cognitive decline and early death. Brain atrophy and retinitis pigmentosa ensue because of neuronal and photoreceptor apoptosis. The CLN3 gene defective in JNCL encodes a novel 438 amino acid protein. Most affected genes harbor a deletion resulting in a truncated protein. CLN3 overexpression in NT2 cells enhances growth, reverses growth inhibition induced by serum starvation and protects from apoptosis induced by vincristine, staurosporine, and etoposide but not from death caused by ceramide. CLN3 modulates endogenous and vincristine-activated ceramide, and therefore suppresses apoptosis by impacting generation of ceramide. |
